Skip to content

A study to access the effect of drug therapy in Recalcitrant Dermatophytosis patients

A Prospective observational study to analyse the treatment response, tolerability and prescribing pattern in patients receiving treatment for Recalcitrant Dermatophytosis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067543
Enrollment
347
Registered
2024-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Priti kochar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All the patients diagnosed with recalcitrant dermatophytosis operational definition of Recalcitrant dermatophytosis refers to relapse, recurrences, reinfection, persistence or chronic infections, and possibly microbiological resistance. 2. Both male and female with established recalcitrant dermatophytosis. 3. Age 18- 60 years.

Exclusion criteria

Exclusion criteria: 1.Patient diagnosed with other autoimmune dermatological disease like psoriasis. 2. Patient with cutaneous adverse drug reactions. 3. Patient with secondary infected tinea infection

Design outcomes

Primary

MeasureTime frame
To analyse the treatment response to antifungals drugs in patients diagnosed with recalcitrant dermatophytosis patients.Timepoint: At baseline and four weeks

Secondary

MeasureTime frame
1. To assess the prescribing pattern of anti-fungal agents and adherence to available treatment guidelines. 2. To evaluate the adverse drug reactions, patient’s adherence to treatment and cost of therapy associated with recalcitrant dermatophytosis medication. 3. To assess the effect of antifungal therapy on the quality of life of patients. 4. Subgroup analysis – Comparison of treatment response in patients receiving different antifungal agents will be done, if feasible.Timepoint: At baseline and four weeks

Countries

India

Contacts

Public ContactDr Manisha Bisht

AIIMS Rishikesh

manisha.phar@aiimsrishikesh.edu.in8475000263

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026